SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of...
Hence then, the article about carsgen announces data of allogeneic bcma car t cell therapy ct0596 for relapsed refractory multiple myeloma at the 2025 ash annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting )
Also on site :
- Heavy police presence in NW suburb with roads blocked due to ‘isolated incident'
- Starbucks Expands Its Summer Menu With 2 Vibrant New Drinks
- With Just Two Looks, Taylor Russell Is Already In the Running for Best-Dressed at Cannes